Kornimate/medical-research-clean huggingface dataset:
a study of ser-155 to treat diarrhea in people on immunotherapy

Conditions: Diarrhea; Enterocolitis

Summary: the purpose of this study is to find out whether ser-155 may be a safe first treatment that causes few or mild side effects for people due to irec.


Eligibility criteria:
inclusion criteria: * age \> 18 years * receipt of ici (single-agent or combination) within the 180 days preceding screening. concurrent treatment with cytotoxic chemotherapy or other tumor-directed agents is permitted. * grade 2 - 3 diarrhea (i.e., increase of at least 4 bowel movements a day above baseline during the screening window), deemed by the treating provider as likely related to ici therapy, with or without concomitant symptoms of grade 1 - 2 colitis (e.g. abdominal pain, bloody or mucoid stools) * able to swallow oral medication * individuals of childbearing potential willing to use a highly effective method of contraception (failure rate of \<1% per year when used consistently and correctly) for 30 days after the last dose of ser-155. * willing to provide written informed consent, comply with the protocol, and understand the potential risks and benefits of study enrollment and treatment. exclusion criteria: * active gi infection, including untreated viral, bacterial or fungal cause(s) of diarrhea. * received immunosuppressive therapies for suspected or confirmed irec, including systemic corticosteroids (either oral or intravenous) and/or infliximab, vedolizumab or ustekinumab * grade 3 colitis symptoms, i.e. severe abdominal pain or peritoneal signs * admitted to the hospital for irec * prednisone (or steroid equivalent) dose \> 10 mg a day for a non-gi irae at time of screening * pre-existing inflammatory bowel disease (e.g. crohn's disease or ulcerative colitis) or microscopic colitis * pregnant or lactating women * any condition that requires ongoing prophylactic or therapeutic antibacterial antibiotics * severe neutropenia, as defined by an absolute neutrophil count (anc) \< 500 cells/mm\^3, at time of screening * treatment with investigational medications used for diarrhea/colitis treatment and microbiome therapeutics within 30 days prior to enrollment * known allergy or intolerance to oral vancomycin * unable to comply with the protocol requirements * any condition that in the opinion of the investigator may increase the risk of study participation and/or may interfere with the interpretation of study results

Keywords: diarrhea ser-155 enterocolitis memorial sloan kettering cancer center 24-231
p3 study of umbilical cord blood cells expanded with mpcs for transplantation in patients with hematologic malignancies

Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease

Summary: the study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.


Eligibility criteria:
inclusion criteria: * patient must have one of the following: * acute myelogenous leukemia (aml) in complete morphological remission at study screening (complete remission with incomplete platelet recovery (crp) acceptable). * acute lymphoblastic leukemia (all) in complete morphological remission at study screening (complete remission with incomplete platelet recovery (crp) acceptable). * non-hodgkin's lymphoma (nhl): high risk subjects with responsive disease after first relapse. high risk includes those with burkitt's lymphoma and those with extensive marrow involvement at diagnosis-precluding autologous transplant. * hodgkin's disease: high risk subjects with responsive disease after first relapse. * minimum karnofsky scale * subject must weigh at least 20 kg * up to 65 years of age * adequate major organ system function exclusion criteria: * pregnancy and/or lactating * suitable, 6/6 hla matched related sibling donor available * previous participation in a stem cell study within last 30 days

Keywords: cord blood stem cells mpc mesoblast expanded aml all nhl leukemia lymphoma
nad therapy for improving memory and brain blood flow in older adults with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this study will provide insight into whether a nutritional supplement, nicotinamide riboside (nr), improves memory and brain blood flow in older adults with low memory abilities. overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.


Eligibility criteria:
inclusion criteria * cognitive function scores consistent with amnestic mild cognitive impairment based on pre-screening evaluation; * age 60-90 years; * mmse score \>24 at time of initial consent; exclusion criteria * blood chemistries indicative of abnormal renal, liver, thyroid and adrenal function; estimated glomerular filtration rate using the mdrd prediction equation must be \>30 ml/min/1.73 m2; * any clinically significant abnormal blood chemistry values as determined by the research nurse or nmpcc nurse practitioner; * major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression within past two years); * neurological or autoimmune conditions affecting cognition (e.g. parkinson's disease, epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel infarct); * concussion within last 2 years and ≥ 3 lifetime concussions; * current systemic medical illnesses (e.g. cardiovascular disease, cancer, renal failure); * prior history of any type of cancer; * substance abuse or dependence (dsm-v criteria); * current use of medications used to treat dementia (e.g., anticholinesterase drugs) or other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting benzodiazepines); * claustrophobia, metal implants, pacemaker or other factors affecting feasibility and/or safety of mri scanning\*; * current smoking (including marijuana) within the past 3 months; * hospitalization as a result of covid-19

Keywords: blood pressure arterial stiffness cerebrovascular function cognitive function
a study of pf-04449913 administered alone in select solid tumors

Conditions: Solid Tumors

Summary: this study examines the effect of a small molecule inhibitor to the sonic hedgehog pathway on select solid tumors.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of advanced/metastatic solid tumor * adequate bone marrow function * adequate renal function * adequate liver function exclusion criteria: * patients with known symptomatic brain metastases requiring steroids * current active treatment on another clinical trial * major surgery or radiation therapy within 4-weeks of starting study treatment

Keywords: pf-04449913 hedgehog inhibitor solid tumor pharmacokinetics safety pharmacodynamics
efficacy and safety of aliskiren in patients with mild to moderate hypertension during exercise

Conditions: Hypertension

Summary: this study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.


Eligibility criteria:
inclusion criteria: * mean sitting systolic blood pressure ≥ 140 mmhg and \< 180 mmhg measured at rest * patients able to exercise and to reach 85% of their predicted heart rate during a standard exercise test on a treadmill according to the bruce protocol exclusion criteria: * patients not confident in exercising or not able to exercise * absolute contraindication to exercise * mean sitting systolic blood pressure ≥ 180 mmhg and/or mean sitting diastolic blood pressure ≥ 110 mmhg measured at rest other protocol-defined inclusion/exclusion criteria applied to the study.

Keywords: hypertension systolic blood pressure exercise test cardiovascular disease aliskiren valsartan
ppio-006 primary tumor resection for iva nsclc

Conditions: Non-small-cell Lung Cancer (NSCLC)

Summary: the goal of this mutli-center observational study is toinvestigate the impact of primary tumor resection (ptr) on the long-term survival of patients with non-small-cell lung cancer (nsclc) and dry pleural dissemination (dpd). the main question it aims to answer is: whether primary tumor resection improve long-term survival of nsclc patients with dry pleural dissemination.

non-small-cell lung cancer (nsclc) patients with dry pleural dissemination have poor survival rates and are generally contraindicated for surgery. previous single-center retrospective studies have suggested that these patients may benefit from primary tumor resection (ptr). however, the evidence supporting ptr is still limited, especially in the era of targeted therapy. this study aimed to investigate the impact of ptr on the long-term survival of patients with nsclc and dpd.

Eligibility criteria:
inclusion criteria: (1) pathologically confirmed primary nsclc with malignant pleural dissemination, (2) no preoperative treatment, (3) age 80 years or younger, (4) clinicopathologic data and follow-up results were complete. exclusion criteria: (1) pleural effusion, contralateral lung metastasis or distant metastasis revealed preoperatively, and (2) with a history of other malignant disease.
association between microvascular resistance and outcomes in patients with obstructive hypertrophic cardiomyopathy

Conditions: Microvascular Dysfunction; Hypertrophic Obstructive Cardiomyopathy; Microcirculation Resistance

Summary: about 60% of patients with hypertrophic cardiomyopathy have microvascular dysfunction. microvascular dysfunction is directly related to prognosis in hypertrophic cardiomyopathy. this new measurement method is microcirculation resistance (mr) based on quantitative flow ratio (qfr), which does not need a pressure guide wire on the basis of angiography. the qfr system is used to evaluate the blood vessels distal pressure and blood flow, and their ratio is microcirculation resistance (mr). the quantitative blood flow fraction measurement system was analyzed by interventional laboratory platform image analysis software (angioplus 2.0). this study is a single-center retrospective cohort study. participants were selected from patients who were diagnosed with hypertrophic obstructive cardiomyopathy in fuwai hospital from january 2020 to november 2021. the risk factor is whether there is microcirculation resistance disorder. the outcome was the major adverse cardiovascular events related to hcm (including all-cause death, heart transplantation, left ventricular pacemaker, and heart failure readmission) that were followed up one year after angiography. aim to further clarify whether there is a certain correlation between microvascular resistance and adverse cardiovascular prognosis.


Eligibility criteria:
inclusion criteria: 1. aged 18-80 years old; 2. patients with hypertrophic obstructive cardiomyopathy undergoing coronary angiography. diagnosis criteria that meet the diagnostic guidelines for hypertrophic obstructive cardiomyopathy: it usually refers to the thickness of the ventricular septum or left ventricular wall measured by two-dimensional echocardiography \> 15 mm, or the thickness of \> 13mm in patients with a clear family history, usually without enlargement of the left ventricular cavity, and the thickening of the left ventricular wall caused by increased loads, such as hypertension, aortic stenosis, and congenital subvalvular septum should be excluded; lvotg\>30 mmhg under quiet or exercise conditions. 3. the informed consent form for the use of sample data of patients admitted to the hospital has been signed; exclusion criteria: 1. no contrast examination is performed for various reasons; 2. missing baseline important information indicators; 3. loss of follow-up;
a study in patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: this study evaluates the effect of medicines for type 2 diabetes and lipids control. this study will require about 6 office visits for lab tests and examinations. all study related medicines and medical examinations will be provided at no cost to the subjects.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis type 2 diabetes mellitus. * women must not be pregnant or breastfeeding during the study and 30 days after the study. * must sign an informed consent form at the study clinic. exclusion criteria: * severe chronic diseases that would prevent from participating and completing the study by investigator's judgement. * use of an investigational drug within 30 days or 5 half lives before first dose of study medication. * insulin use for \> 1 week in past 3 months.

Keywords: type 2 diabetes type ii
antihypertensive efficacy and safety of candesartan/hct 32/25 mg in comparison with individual components and placebo

Conditions: Hypertension

Summary: the aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (hct) 25 mg to that of candesartan 32 mg alone, hct 25 mg alone and placebo in hypertensive adults.


Eligibility criteria:
inclusion criteria: * patients will be eligible for enrolment into the study (visit 1) if they fulfil all of the following criteria: * provision of signed informed consent * primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs (substances), which the patient and the physician are willing to withdraw at enrolment and replace with placebo. * mean sitting dbp 90-114 mmhg (value calculated in the ecrf) at visits 1 and 2 * patients will be eligible for randomisation (visit 4) if they fulfil the following criterion: * mean sitting dbp of 90-114 mmhg (value calculated in the ecrf) at the end of the 4-week single-blind placebo run-in period. the run-in period should not be shorter than 4 weeks. exclusion criteria: * pregnant or lactating women, or women of childbearing potential not practising an adequate method of contraception eg, intrauterine device, oral contraception or progesterone implant. pregnancy must be excluded by a negative pregnancy test at visit 1. * secondary or malignant hypertension * sitting sbp of 180 mmhg or more * myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack within 6 months before enrolment * angina pectoris requiring more treatment than short-acting nitrates * chronic use of nsaids * aortic or mitral valve stenosis * cardiac failure requiring treatment * cardiac arrhythmia requiring treatment * gout * renal artery stenosis or kidney transplantation * intravascular volume depletion * hypersensitivity to any component of the investigational products or to any sulphonamide derived drugs * concomitant disease which may interfere with the assessment of the patient * past or present alcohol or drug abuse, or any condition associated with poor compliance that in the opinion of the investigator might affect the patient's participation in the study * chronic liver disease * concomitant or previous treatment with any other investigational drug within 20 days of enrolment * previous enrolment in the present study

Keywords: blood pressure reduction combination therapy candesartan cilexetil hydrochlorothiazide
serratus anterior plane block versus intercostal block

Conditions: Pain, Postoperative

Summary: pain after thoracotomy is the most severe pain experienced by the patient. good pain control after the operation provides comfortable respiration and reduces the development of chronic pain and complications. we aimed to compare sapb with ibregarding postoperative visual analog scale (vas) scores and analgesic consumption in patients undergoing thoracotomy operation.

patients who underwent thoracotomy operation in our hospital between may 2016 and june 2017 were examined. a retrospective evaluation was made of the data that was retrieved from the records of a total of 49 patients aged 18-75 years, asa i-iii, who were applied with intercostal (ib) or serratus anterior plane(sapb) for a thoracotomy operation. the patient information was retrieved from the patient records and anesthesia block forms. the data were examined in respect of age, sex, height, weight, asa, operation type, operating time, the amount of postoperative analgesic consumption, vas at 1.,2.,4.,6.,12.,24. hours and complications (atelectasis, nausea, vomiting, hypotension and bradycardia). statistical analysis was performed using the spss program for mac, version 17.0 (spss,chicago,il). descriptive statistics are presented as mean and sd, and as the number of cases (n) and the corresponding percentage (%) for nominal variables. t tests were performed for normally continuous variables. the mann-whitney u test was used for non-parametric variables. a value of p \< 0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: 1. thoracotomy operation 2. a.serratus anaterior plane block b.intercostal block exclusion criteria: 1. missing data 2. written consent 3. rethoracotomy

Keywords: pain, thoracotomy
screening for atrial fibrillation (af)-potential patients to increase af detection rate

Conditions: Atrial Fibrillation

Summary: to assess the prevalence of all (prevalent and paroxysmal) undiagnosed atrial fibrillation (af) in a japanese population with a moderate-to-high risk of stroke


Eligibility criteria:
inclusion criteria: * age ≥ 65 and one or more of the following: hypertension, prior stroke or transient ischemic attack, congestive heart failure, diabetes mellitus, and/or vascular disease exclusion criteria: * age \< 65 years, individuals with af or a history of af, or individuals taking anti-arrhythmic drugs other protocol defined inclusion/exclusion criteria could apply
evaluate performance of callisto eye vs. wavetec analyzor

Conditions: Cataract

Summary: the goal of this clinical trial is to evaluate two separate operating room cataract measuring tools in predicting the residual astigmatism (prediction error) in patients with corneal astigmatism. the main question it aims to answer is: show the refractive predictability comparing the use of operating room cataract toric lens placement tools against the standard manual technique. participants will be implanted with the tecnis toric ii iol lens model zcu; the second eye, if applicable, is to be implanted within 45 days of the first-eye surgery. researchers will compare two operating room cataract lens placement tools: the zeiss callisto vs. the wavetec analyzor to determine refractive predictability.

to evaluate two separate operating room cataract measuring tools in predicting the residual astigmatism (prediction error) in patients with corneal astigmatism (maximum allowable up to 3.0d) comparing the zeiss callisto eye and the wavetec analyzor at the one-month post-operative visit. both surgery rooms will be using veracity, iol master and zeiss opmi lumera i operating room microscopes. operating room #1 will be utilizing the zeiss callisto eye for axis alignment, along with veracity and iol master for lens selection, and operating room #2 will be utilizing the wavetec analyzor for lens selection and axis alignment. procedure times for the zeiss callisto eye and the wavetec analyzor will be obtained by using a start/stop watch, including phakic power calculation and toric positioning. in addition, the suction on (start of lensx), treatment time of lensx in seconds, suction off (end of lensx), start time of primary incision, the beginning of phaco, end of phaco, cde (combined diffused energy) total and the end time of procedure will all be documented. all times will be analyzed and compared between operating room #1 and operating room #2.

Eligibility criteria:
inclusion criteria: * unilateral or bilateral cataract extraction with single piece hydrophobic acrylic posterior capsular intraocular lens correcting astigmatism. * clear intraocular media other than cataract. * willing and able to complete all required postoperative visits. * able to comprehend and sign a statement of informed consent in english. exclusion criteria: * ocular disease or pathology that, in the opinion of the investigator, will affect the post-operative visual acuity and manifest refraction. * prior intraocular or corneal refractive surgery, corneal transplant, or retinal detachment.

Keywords: cataract toric cataract surgery residual astigmatism
csems vs. neps in stricture of biliary anastomosis after liver transplantation

Conditions: Stenosis of the Bilio-biliary Anastomosis After Orthotopic Liver Transplantation

Summary: stenosis at the bilio-biliary anastomosis occurs in up to 30% of patients after orthotopic liver transplantation. this study compares endoscopic treatment with implantation of multiple plastic endoprostheses vs. use of a removable, covered self-expandable metal stent (csems).

this is a multi-center randomised trial.

Eligibility criteria:
inclusion criteria: * post-olt stenosis of the bilio-biliary anastomotic exclusion criteria: * non-anastomotic stricture * stent implatation technically not feasible

Keywords: csems neps ercp biliary stricture biliary stenosis liver transplantation
evaluate the efficacy and safety of 'immuncell-lc' in patients undergoing liver transplantation

Conditions: Liver Transplantation

Summary: the purpose of this study is to investigate and validate the maximum tolerated dose (mtd) or maximum available dose (mfd), safety and efficacy on patients with hepatocellular carcinoma beyond milan criteria who undergo liver transplantation.

ilc-iit-07 is open-label, phase 1/2 clinical trial to confirm safety on patients with hepatocellular carcinoma beyond milan criteria who undergo liver transplantation. for primary outcome, maximum feasible dose (mfd) or maximum tolerated dose (mtd) will be evaluated. for secondary outcome, time to recurrence(ttr), recurrence-free survival(rfs), overall survival(os) will be evaluated.

Eligibility criteria:
inclusion criteria: * patients who are more than 20 and less than 80 years old. * patients whose expected life expectancy is at least 16 weeks (4 months). * patients who receive liver transplants exceeding the milan criteria. * ecog performance status (ecog-ps) score is 0-2. * patients who satisfy the following conditions of the blood test and kidney, liver function test. absolute neutrophil count \> 500x10\^6l hemoglobin ≥ 7.5 g/dl platelet count \> 20,000/㎣ total bilirubin \< 15mg/㎗ •patients who have agreed to participate in the study voluntarily by signing on informed consent form. exclusion criteria: * patients who have received in vitro radiation therapy, systemic chemotherapy within 4 weeks based on sign date of informed consent form. * patients who undergo abo incompatible liver transplantation. * patients who had previously administered cell therapy. * patients who are confirmed with acquired immune deficiency syndrome (aids). * patients who are currently receiving dialysis. * patients who participated in another clinical trial and received treatment in 4 weeks or have a plan for administration of another clinical trial treatment since informed consent form sign date. * patients who have uncontrollable or serious disease. * patients who are unable to use appropriate methods of contraception during the study period. * patient whose tumor has not been removed or liver metastasis is confirmed.